YvonneHsiao-Fan(Lam)SadaMD

Gastrointestinal Cancer, Hematologic Oncology

Instructor, Hematology & Oncology, Baylor College of Medicine

Dr. Sada is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
2002 Holcombe Blvd
Dept Of Hematology & Oncology Va 111 H
Houston, TX 77030
Phone+1 713-794-7111

Fax+1 713-794-7733

Baylor College of MedicineFellowship, Hematology and Medical Oncology, 2008 - 2011
Baylor College of MedicineResidency, Internal Medicine, 2005 - 2008
University of Rochester School of Medicine and DentistryClass of 2005

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Meclizine for Hepatocellular Carcinoma Start of enrollment: 2017 Oct 13
Active, not recruiting
Phase 1

PubMed

53 citations
Primary care and communication in shared cancer care: a qualitative study.
Yvonne H. Sada, Richard L. Street, Hardeep Singh, Rachel E Shada, Aanand D. Naik
The American Journal of Managed Care. 2011-04-19
417 citations
Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans is Associated With Nonalcoholic Fatty Liver Disease.
Sahil Mittal, Hashem B. El-Serag, Yvonne H. Sada, Fasiha Kanwal, Zhigang Duan
Clinical Gastroenterology and Hepatology. 2016-01-01
197 citations
Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population.
Sahil Mittal, Yvonne H. Sada, Hashem B. El-Serag, Fasiha Kanwal, Zhigang Duan
Clinical Gastroenterology and Hepatology. 2015-03-01

Resilient Cancer Patient Grateful for Houston VAMarch 20th, 2023
A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal CancerApril 4th, 2024